These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 12052096)

  • 1. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.
    Ginsberg G; Lowe S
    Pharmacoeconomics; 2002; 20(6):367-87. PubMed ID: 12052096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.
    Ackerman SJ; Sullivan EM; Beusterien KM; Natter HM; Gelinas DF; Patrick DL
    Pharmacoeconomics; 1999 Feb; 15(2):179-95. PubMed ID: 10351191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
    Tavakoli M; Malek M
    J Neurol Sci; 2001 Oct; 191(1-2):95-102. PubMed ID: 11676998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
    Thakore NJ; Pioro EP; Udeh BL; Lapin BR; Katzan IL
    Value Health; 2020 Dec; 23(12):1543-1551. PubMed ID: 33248509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALS/MND and the perspective of health economics.
    Gray AM
    J Neurol Sci; 1998 Oct; 160 Suppl 1():S2-5. PubMed ID: 9851642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fair innings for NICE?
    Freemantle N; Bloor K; Eastaugh J
    Pharmacoeconomics; 2002; 20(6):389-91. PubMed ID: 12052097
    [No Abstract]   [Full Text] [Related]  

  • 9. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2000; (2):CD001447. PubMed ID: 10796796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD001447. PubMed ID: 22419278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2001; (4):CD001447. PubMed ID: 11687111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.
    Messori A; Trippoli S; Becagli P; Zaccara G
    Pharmacoeconomics; 1999 Aug; 16(2):153-63. PubMed ID: 10539396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y; Takahashi Y
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness associated with amyotrophic lateral sclerosis: some questions and answers pending.
    Fiorentino G; Esquinas AM
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):315-316. PubMed ID: 29191046
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy.
    Georgoulopoulou E; Fini N; Vinceti M; Monelli M; Vacondio P; Bianconi G; Sola P; Nichelli P; Mandrioli J
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Sep; 14(5-6):338-45. PubMed ID: 23373475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis.
    Hodgkinson VL; Lounsberry J; Mirian A; Genge A; Benstead T; Briemberg H; Grant I; Hader W; Johnston WS; Kalra S; Linassi G; Massie R; Melanson M; O'Connell C; Schellenberg K; Shoesmith C; Taylor S; Worley S; Zinman L; Korngut L
    Can J Neurol Sci; 2018 Nov; 45(6):652-659. PubMed ID: 30430962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole.
    Riviere M; Meininger V; Zeisser P; Munsat T
    Arch Neurol; 1998 Apr; 55(4):526-8. PubMed ID: 9561981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
    Bellingham MC
    CNS Neurosci Ther; 2011 Feb; 17(1):4-31. PubMed ID: 20236142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvements in the multidisciplinary care are beneficial for survival in amyotrophic lateral sclerosis (ALS): experience from a tertiary ALS center.
    Klavžar P; Koritnik B; Leonardis L; Dolenc Grošelj L; Kirbiš M; Ristić Kovačič S; Klinar P; Pohar Perme M; Zidar J
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 May; 21(3-4):203-208. PubMed ID: 32248716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.